Faron Pharmaceuticals Oy (DI) (FARN) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 Feb 2016 07:00 AM
RNS
Notice of Preliminary Results
07 Jan 2016 07:00 AM
RNS
Top-line results from Japanese study of Traumakine
29 Dec 2015 07:00 AM
RNS
First Patient recruited in Phase III ARDS Study
21 Dec 2015 07:00 AM
RNS
Faron Awarded ?1.5 million Tekes Funding
30 Nov 2015 07:00 AM
RNS
Key Publication in Journal of Immunology
17 Nov 2015 07:30 AM
RNS
Admission to AIM and first day of dealings

Faron Pharmaceuticals Oy is a Finland-based, clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that leverage the patient's own immune system, with a lead asset, bexmarilimab, currently in Phase I/II clinical trials. Faron Pharmaceuticals is listed under the ticker FARN.

FARN share price launched at 230p in 2015.

 

UK 100

Latest directors dealings